11/01/2019 11:47:00

Net Asset Value(s)

BlackRock Smaller Companies Trust Plc - Net Asset Value(s)

PR Newswire

 NET ASSET VALUE

BLACKROCK SMALLER COMPANIES TRUST PLC

549300MS535KC2WH4082

The unaudited net asset values for BlackRock Smaller Companies Trust plc at

close of business on 10 January 2019 were:

1351.29p Capital only and including debt at par value

1343.63p Capital only and including debt at fair value

1371.07p Including current year income and debt at par value

1363.40p Including current year income and debt at fair value

Notes:

1. Investments have been valued on a bid price basis.

2. The total number of ordinary shares in issue excluding treasury

shares is 47,879,792. The total amount of ordinary shares

held in treasury is 2,113,731.

3. For the latest daily net asset value, previous month end performance

statistics, asset allocation and ten largest holdings of the BlackRock managed

Investment Trusts; see BLRKINDEX on Reuters or page 8800 on ICB (Topic 3).

Related content
14 Jun - 
Net Asset Value(s)
13 Jun - 
Net Asset Value(s)
12 Jun - 
Net Asset Value(s)
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

14 Jun E:BRSC
13 Jun E:BRSC
12 Jun E:BRSC
11 Jun E:BRSC
10 Jun E:BRSC
07 Jun E:BRSC
06 Jun E:BRSC
05 Jun E:BRSC
04 Jun E:BRSC

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma
2
REV DEADLINE: Rosen, a Highly Ranked Law Firm, Reminds Revlon, Inc. Investors of Important July 15th Deadline in Securities Class Action – REV
3
Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association
4
FSIS Recall 069-2019 Foreign Matter Contamination: RUIZ FOODS PRODUCTS INC. RECALLS BACON BREAKFAST WRAP PRODUCTS DUE TO POSSIBLE FOREIGN MATTER CONTAMINATION
5
Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress

Related stock quotes

Blackrock Smaller CO Tru.. 1,482.00 0.5% Stock price increasing

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 June 2019 04:31:09
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB2 - 2019-06-16 05:31:09 - 2019-06-16 04:31:09 - 1000 - Website: OKAY